New Cell Lines…is it new?
(taken from DR. Sherri Tenpenny’s “The Hidden Hazards of the New Flu Vaccine, OptaFlu”)
First described in the mid-1990s and still in the experimental stages, the new technology has drawn all major players in the vaccine industry into attempts to develop cell culture technology for flu shots. The methodology can be rapidly expanded in times when the government thinks there is an emergency need for any vaccine that is made from eggs.
Although new for flu shots, cell-culture technology is hardly new. It has been used since the 1950s for the production of polio, measles, mumps, and tetanus vaccines. Cell-line technology has not been used for flu shots primarily for logistical reasons: It would require a complete retooling of existing production facilities. None of the manufacturers have been willing to invest the hundreds of millions of dollars and the five to seven years required to build new vaccine plants. But with the threat of a pandemic, and the government providing tens of billions of dollars to produce a bird flu vaccine, the funding for the capital improvements allowed manufacturers to rapidly proceed.
The FDA is fully aware that the new cell substrates made from animal tissues come with risks that in many ways are no different from the risks associated with using eggs. The cells can become contaminated with adventitious viruses that are potentially deadly. An FDA memo acknowledges the risks:
“The experience in the early 1960s with SV40 contamination of poliovirus and adenovirus vaccines and the continuing questions regarding whether SV40 could be responsible for some human neoplasms [cancers] underscores the importance of keeping viral vaccines free of adventitious agents [viral contaminants]. This is particularly important when there is a theoretical potential for contamination of a vaccine with viruses that might be associated with neoplasia [cancer]…It is unclear whether cell substrates have a greater or lower risk [of contamination] than other types of cells…However, if their growth in tissue culture is not well controlled, there may exist additional opportunities for contamination of cells with a longer lifespan.” (1)
And it gets worse. The same FDA memo goes on to say:
“In addition to the possibility of contamination of cell substrates…the use of immortalized, neoplastic human cells to develop [vaccines] raises theoretical concerns with regard to possible contamination with TSE/BSE agents.”(2)
TSE is Transmissible Spongiform Encephalopathy, a condition that includes a group of rare degenerative brain disorders characterized by tiny holes in the brain tissues, giving a “spongy” appearance when viewed under a microscope. When this condition occurs in cows it is called Bovine Spongiform Encephalopathy, commonly known as “mad cow disease.” In a study published in 2004, researchers found that any cell line could potentially support the propagation of TSE agents.(3)
Clearly, CBER, a division of the FDA, is aware and disquieted over the carcinogenic potential of animal cells and wants manufacturers to take every available precautionary step to eliminate the cells from the vaccine final product. The FDA admits serious concerns about contamination of all types of cell lines. The question that begs an answer is, knowing the cancer-causing potential of the cell lines and the cancer-causing risks of contaminants in the cell lines, why is this technology being promoted? Or better, why is the FDA allowing its use at all?
Despite substantial evidence—and even admissions of concern—the FDA appears to be flagrantly ignoring the potential for harm to vaccine recipients through this technology and is recklessly approving the use of these product.